These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37579970)

  • 1. Inhibiting Wnt Signaling Reduces Cholestatic Injury by Disrupting the Inflammatory Axis.
    Ayers M; Kosar K; Xue Y; Goel C; Carson M; Lee E; Liu S; Brooks E; Cornuet P; Oertel M; Bhushan B; Nejak-Bowen K
    Cell Mol Gastroenterol Hepatol; 2023; 16(6):895-921. PubMed ID: 37579970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
    Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
    Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.
    Pradhan-Sundd T; Kosar K; Saggi H; Zhang R; Vats R; Cornuet P; Green S; Singh S; Zeng G; Sundd P; Nejak-Bowen K
    Hepatology; 2020 May; 71(5):1732-1749. PubMed ID: 31489648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of WNT/Beta-Catenin Signaling and Regulation of the Farnesoid X Receptor/Beta-Catenin Complex After Murine Bile Duct Ligation.
    Zhang R; Nakao T; Luo J; Xue Y; Cornuet P; Oertel M; Kosar K; Singh S; Nejak-Bowen K
    Hepatol Commun; 2019 Dec; 3(12):1642-1655. PubMed ID: 31832572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone ameliorates ANIT-induced cholestatic liver injury via modulation of FXR, NF-кB/TNF-α, and Wnt/GSK-3β/β-catenin signaling pathways.
    Abdulaal WH; Omar UM; Zeyadi M; El-Agamy DS; Alhakamy NA; Ibrahim SRM; Almalki NAR; Asfour HZ; Al-Rabia MW; Mohamed GA; Elshal M
    Toxicol Appl Pharmacol; 2024 Sep; 490():117038. PubMed ID: 39019095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
    Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
    Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.
    Iruzubieta P; Goikoetxea-Usandizaga N; Barbier-Torres L; Serrano-Maciá M; Fernández-Ramos D; Fernández-Tussy P; Gutiérrez-de-Juan V; Lachiondo-Ortega S; Simon J; Bravo M; Lopitz-Otsoa F; Robles M; Ferre-Aracil C; Varela-Rey M; Elguezabal N; Calleja JL; Lu SC; Milkiewicz M; Milkiewicz P; Anguita J; Monte MJ; Marin JJG; López-Hoyos M; Delgado TC; Rincón M; Crespo J; Martínez-Chantar ML
    JHEP Rep; 2021 Jun; 3(3):100276. PubMed ID: 33997750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Wang Y; Aoki H; Yang J; Peng K; Liu R; Li X; Qiang X; Sun L; Gurley EC; Lai G; Zhang L; Liang G; Nagahashi M; Takabe K; Pandak WM; Hylemon PB; Zhou H
    Hepatology; 2017 Jun; 65(6):2005-2018. PubMed ID: 28120434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PGC1α deficiency reverses cholestasis-induced liver injury via attenuating hepatic inflammation and promoting bile duct remodeling.
    Li D; Ye C; Liu P; Sun T; Qin Y; Wan X
    Acta Histochem; 2023 Dec; 125(8):152097. PubMed ID: 37813066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
    Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
    Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
    Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
    JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
    Blokker BA; Maijo M; Echeandia M; Galduroz M; Patterson AM; Ten A; Philo M; Schungel R; Gutierrez-de Juan V; Halilbasic E; Fuchs C; Le Gall G; Milkiewicz M; Milkiewicz P; Banales JM; Rushbrook SM; Mato JM; Trauner M; Müller M; Martínez-Chantar ML; Varela-Rey M; Beraza N
    Hepatology; 2019 Feb; 69(2):699-716. PubMed ID: 30229970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt-Signaling Inhibitor Wnt-C59 Suppresses the Cytokine Upregulation in Multiple Organs of Lipopolysaccharide-Induced Endotoxemic Mice via Reducing the Interaction between β-Catenin and NF-κB.
    Jang J; Song J; Sim I; Kwon YV; Yoon Y
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
    Weerachayaphorn J; Luo Y; Mennone A; Soroka CJ; Harry K; Boyer JL
    J Hepatol; 2014 Jan; 60(1):160-6. PubMed ID: 23978715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
    Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
    Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
    Kimura M; Nishikawa K; Osawa Y; Imamura J; Yamaji K; Harada K; Yatsuhashi H; Murata K; Miura K; Tanaka A; Kanto T; Kohara M; Kamisawa T; Kimura K
    Hepatol Commun; 2022 Oct; 6(10):2732-2747. PubMed ID: 35855613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sortilin 1 Loss-of-Function Protects Against Cholestatic Liver Injury by Attenuating Hepatic Bile Acid Accumulation in Bile Duct Ligated Mice.
    Li J; Woolbright BL; Zhao W; Wang Y; Matye D; Hagenbuch B; Jaeschke H; Li T
    Toxicol Sci; 2018 Jan; 161(1):34-47. PubMed ID: 28453831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease.
    Lemberger UJ; Fuchs CD; Karer M; Haas S; Stojakovic T; Schöfer C; Marschall HU; Wrba F; Taketo MM; Egger G; Trauner M; Österreicher CH
    Oncotarget; 2016 Dec; 7(52):86985-86998. PubMed ID: 27895309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.